OR WAIT null SECS
August 14, 2018
Drug product approval from FDA follows previous approvals from European and Japanese authorities.
August 13, 2018
The new drug, Onpattro (patisiran), by Alnylam Pharmaceuticals, is in a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.
August 06, 2018
The companies will collaborate on the discovery, development, and commercialization of cell therapies for cancer.
August 02, 2018
Materials in contact with a drug must be fully characterized to ensure they do not negatively affect the safety and efficacy of the product.
Frustrated by slow market adoption, Gottlieb maps out new plan for biosimilar competition.
Development costs and time to market continue to put pressure on the biopharma industry, driving the need for innovation in methods and technologies.
August 01, 2018
CMOs have been active over the past year in expanding their biologics production and capabilities.
July 19, 2018
The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.
In launching FDA’s Biosimilar Action Plan, Gottlieb takes innovator companies to task for delaying competitive biosimilar products.
July 18, 2018
CELLforCURE will produce cancer CAR-T treatments for Novartis at a manufacturing facility in Les Ulis (Essonne), France.